BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24530596)

  • 1. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
    Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
    Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
    J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats.
    Pun CK; Huang HC; Chang CC; Chuang CL; Yen CH; Hsu SJ; Lee FY; Hou MC; Huang YH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes.
    Hsin IF; Huang HC; Chang CC; Hsu SJ; Lee FY; Huo TI; Chuang CL; Hou MC; Lee SD
    Clin Sci (Lond); 2018 Nov; 132(22):2391-2405. PubMed ID: 30348829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
    Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
    Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
    Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats.
    Liu SY; Huang CC; Huang SF; Liao TL; Kuo NR; Yang YY; Li TH; Liu CW; Hou MC; Lin HC
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis.
    Hsu SJ; Wang SS; Hsin IF; Lee FY; Huang HC; Huo TI; Lee WS; Lin HC; Lee SD
    Clin Sci (Lond); 2014 May; 126(9):633-44. PubMed ID: 24063570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.
    Schwabl P; Seeland BA; Riedl F; Schubert TL; Königshofer P; Brusilovskaya K; Petrenko O; Hofer B; Schiefer AI; Trauner M; Peck-Radosavljevic M; Reiberger T
    Adv Med Sci; 2022 Mar; 67(1):154-162. PubMed ID: 35272246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats.
    Huang HC; Tsai MH; Chang CC; Pun CK; Huang YH; Hou MC; Lee FY; Hsu SJ
    Clin Sci (Lond); 2021 Dec; 135(24):2709-2728. PubMed ID: 34870313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NADPH oxidase 1/4 inhibition attenuates the portal hypertensive syndrome via modulation of mesenteric angiogenesis and arterial hyporeactivity in rats.
    Deng W; Duan M; Qian B; Zhu Y; Lin J; Zheng L; Zhang C; Qi X; Luo M
    Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):255-265. PubMed ID: 30413372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.
    Angermayr B; Fernandez M; Mejias M; Gracia-Sancho J; Garcia-Pagan JC; Bosch J
    Gut; 2007 Apr; 56(4):560-4. PubMed ID: 16854998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen improves the hyperdynamic circulation and hyporeactivity of mesenteric arteries by alleviating oxidative stress in partial portal vein ligated rats.
    Zhang B; Zhang CG; Zhou QB; Chen W; Wu ZY
    World J Gastroenterol; 2013 Oct; 19(40):6863-8. PubMed ID: 24187462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
    Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
    Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
    Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
    United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
    Uschner FE; Ranabhat G; Choi SS; Granzow M; Klein S; Schierwagen R; Raskopf E; Gautsch S; van der Ven PF; Fürst DO; Strassburg CP; Sauerbruch T; Diehl AM; Trebicka J
    Sci Rep; 2015 Sep; 5():14573. PubMed ID: 26412302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.